All (n = 55) | Ultrasound-defined active synovitis | P valuea | ||
---|---|---|---|---|
Yes (n = 25) | No (n = 30) | |||
Age (years) | 52.0 (44.0 to 61.5) | 51.0 (44.0 to 59.0) | 55.0 (47.0 to 63.3) | 0.279 |
Sex (male) | 13 (23.6%) | 8 (32.0%) | 5 (16.7%) | 0.311 |
Body mass index | 25.2 (23.2 to 28.3) | 26.0 (24.0 to 29.0) | 24.0 (23.1 to 27.4) | 0.122 |
Disease duration (months) | 90.0 (57.1 to 148.9) | 86.3 (60.3 to 153.8) | 93.7 (54.9 to 145.2) | 0.659 |
Remission duration (months) | 37 (8 to 58) | 29 (7.50 to 50.00) | 37 (9.00 to 66.25) | 0.537 |
DAS28-ESR | 2.03 (1.67 to 2.44) | 2.24 (1.94 to 2.55) | 1.92 (1.56 to 2.16) | 0.060 |
DAS28-CRP | 1.42 (1.38 to 1.58) | 1.54 (1.39 to 1.67) | 1.40 (1.23 to 1.48) | 0.023 |
SDAI | 4.51 (3.56 to 6.21) | 5.03 (4.11 to 7.70) | 4.14 (2.69 to 6.02) | 0.064 |
Patient global assessment | 30 (10 to 30) | 30 (10 to 30) | 30 (10 to 30) | 0.767 |
Physician global assessment | 10 (10 to 30) | 10 (10 to 30) | 10 (10 to 30) | 0.322 |
VAS pain | 9 (2 to 25) | 14 (4 to 23) | 5 (2 to 25) | 0.251 |
VAS fatigue | 15 (2 to 47) | 14 (0 to 43) | 16 (3 to 57) | 0.529 |
mHAQ | 0.1 (0.0 to 0.3) | 0.1 (0.0 to 0.3) | 0.0 (0.0 to 0.3) | 0.570 |
ESR (mm/1 hour) | 9 (7 to 15) | 10 (7 to 20) | 9 (6 to 12) | 0.498 |
CRP (mg/dl) | 0.10 (0.03 to 0.33) | 0.11 (0.03 to 0.49) | 0.09 (0.04 to 0.23) | 0.728 |
Rheumatoid factor | 39 (71%) | 18 (72%) | 21 (70%) | 0.900 |
Rheumatoid factor (IU) | 103 (22 to 229) | 84 (22 to 240) | 113 (23 to 215) | 0.980 |
ACPA | 47 (86%) | 23 (92%) | 24 (80%) | 0.383 |
ACPA titers (IU/ml) | 254 (109 to 1575) | 270 (121 to 1352) | 226 (83 to 1600) | 0.645 |
Prednisone | 15 (27%) | 3 (12%) | 12 (40%) | 0.044 |
DMARDs | 45 (82%) | 22 (88%) | 23 (77%) | 0.463 |
Biological therapy | 23 (42%) | 9 (36%) | 14 (47%') | 0.600 |
SH (grade ≥2) | 31 (56%) | 25 (100%) | 6 (20%) | <0.001 |
PDUS | 35 (64%) | 25 (100%) | 10 (33%) | <0.001 |